Agent for inducing interferon production containing lactic acid bacteria

Patent metadata

Field	Value
Publication number	US-2019192584-A1
Application number	US-201916290581-A
Country	US
Kind code	A1
Filing date	Mar 1, 2019
Priority date	Dec 28, 2010
Publication date	Jun 27, 2019
Grant date	—

Abstract

This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as Lactococcus garvieae NBRC100934, Lactococcus lactis subsp. cremoris JCM16167, Lactococcus lactis subsp. cremoris NBRC100676, Lactococcus lactis subsp. hordniae JCM1180, Lactococcus lactis subsp. hordniae JCM11040, Lactococcus lactis subsp. lactis NBRC12007, Lactococcus lactis subsp. lactis NRIC1150, Lactococcus lactis subsp. lactis JCM5805, Lactococcus lactis subsp. lactis JCM20101, Leuconostoc lactis NBRC12455, Leuconostoc lactis NRIC1540, Pediococcus damnosus JCM5886, or Streptococcus thermophilus TA-45.

First claim

1 . A method for preventing or treating virus infection, which comprises administering Lactococcus lactis JCM5805 or Lactococcus lactis JCM20101 capable of activating plasmacytoid dendritic cells (pDCs) and inducing IFN prosuction or a cultured or processed product thereof to a subject.

2 . The method according to claim 1 , wherein the processed product of lactic acid bacteria is a fraction containing nucleic acids.

3 . The method according to claim 1 , wherein Lactococcus lactis JCM5805 or Lactococcus lactis JCM20101 is orally administered.

4 . The method according to claim 1 , wherein IFN is type I IFN or type III IFN.

5 . The method according to claim 1 , wherein IFN is at least one member selected from the group consisting of IFN-α, IFN-β, and IFN-λ.

6 . The method according to claim 3 , wherein, when Lactococcus lactis JCM5805 or Lactococcus lactis JCM20101 is orally administered, Lactococcus lactis JCM5805 or Lactococcus lactis JCM20101 is highly tolerant to the gastric juice or intestinal juice and is capable of reaching the intestinal canal alive.

Assignees

• Kirin Holdings Kk

Inventors

• Fujiwara Daisuke
• JONAI Kenta
• Sugimura Tetsu

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A23C19/062

  using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures · CPC title

• A61K35/744 Primary

  Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs · CPC title